FDA inspection
Zhejiang Novus Pharmaceuticals Co., Ltd.: FDA inspection ending Nov 8, 2024
FDA inspection 1256361 · Voluntary Action Indicated (VAI) · Shaoxing
Key facts
| Inspection ID | 1256361 |
|---|---|
| Firm | Zhejiang Novus Pharmaceuticals Co., Ltd. |
| FEI number | 3013567704 |
| Address | Yuezhong Xintiandi, Mashanzhen Yuecheng; Mashanzhen Yuecheng |
| City | Shaoxing |
| Country | China |
| Fiscal year | 2025 |
| Inspection end date | Nov 8, 2024 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data